Skip to main content
Terug
SHEZF logo

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Datakwaliteit: 100%
Overbought
SHEZF
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 0,47
€ 0,00 (0,00%)
Marktkapitalisatie: 690,29M
Dagbereik
€ 0,47 € 0,72
52-Weeksbereik
€ 0,47 € 0,72
Volume
25
50D / 200D Gem.
€ 0,47 / € 0,47
Vorige Slotkoers
€ 0,47

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 1,1 0,3
P/B 0,1 2,9
ROE % 5,4 3,7
Net Margin % 12,3 3,8
Rev Growth 5Y % -0,2 10,0
D/E 0,3 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 0,53
€ 0,53 – € 0,53
 6,2 B 1
FY2026 € 0,49
€ 0,49 – € 0,49
 5,8 B 1

Belangrijkste Punten

Revenue declined -0,24% annually over 5 years
Debt/Equity of 0,25 — conservative balance sheet
Generating 1,99B in free cash flow
P/E of 1,07 — trading at a low valuation
Cash machine — converts 307,91% of earnings into free cash flow
Capital efficient — spends only 3,84% of revenue on capex

Groei

Revenue Growth (5Y)
-0,24%
Revenue (1Y)-3,03%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
5,38%
ROIC3,68%
Net Margin12,25%
Op. Margin14,04%

Veiligheid

Debt / Equity
0,25
Current Ratio2,60
Interest Coverage5,25

Waardering

P/E Ratio
1,07
P/B Ratio0,06
EV/EBITDA2,67
Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -3,03% Revenue Growth (3Y) -14,12%
Earnings Growth (1Y) N/A Earnings Growth (3Y) -5,71%
Revenue Growth (5Y) -0,24% Earnings Growth (5Y) -10,86%
Profitability
Revenue (TTM) 5,28B Net Income (TTM) 646,74M
ROE 5,38% ROA 3,73%
Gross Margin 33,26% Operating Margin 14,04%
Net Margin 12,25% Free Cash Flow (TTM) 1,99B
ROIC 3,68% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,25 Current Ratio 2,60
Interest Coverage 5,25 Dividend Yield 0,03%
Valuation
P/E Ratio 1,07 P/B Ratio 0,06
P/S Ratio 0,13 PEG Ratio -0,04
EV/EBITDA 2,67 Dividend Yield 0,03%
Market Cap 690,29M Enterprise Value 1,98B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 5,28B 5,45B 7,16B 6,37B 5,33B
Net Income 646,74M -783,26M 727,43M 240,79M 1,02B
EPS (Diluted) 0,44 -0,53 0,50 0,16 0,76
Gross Profit 1,76B 944,92M 2,33B 2,03B 2,09B
Operating Income 741,31M -860,91M 828,62M 227,47M 1,33B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 17,34B 19,20B 20,81B 19,11B 19,03B
Total Liabilities 5,14B 7,22B 8,41B 7,58B 7,34B
Shareholders' Equity 12,15B 11,91B 12,31B 11,41B 11,57B
Total Debt 2,98B 3,78B 6,46B 5,65B 5,65B
Cash & Equivalents 1,69B 1,85B 2,14B 2,94B 2,71B
Current Assets 9,62B 10,60B 12,39B 10,77B 9,13B
Current Liabilities 3,70B 4,99B 5,58B 4,79B 3,61B

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#286 of 826
51
Value Defensive Investing (Benjamin Graham)
#175 of 709
45

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026